Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics

References

• Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality And Prevalence Worldwide IARC. (CancerBase No. 5. Version 2.0). IARCPress, Lyon, France (2004).
   Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: GLOBOCAN 2000. Int. J. Cancer94(2), 153–156 (2001).
   PubMed Web of Science ®Google Scholar
• Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol.2(9), 533–543 (2001).
   PubMed Web of Science ®Google Scholar
• El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology127(5 Suppl. 1), S27–S34 (2004).
   PubMed Web of Science ®Google Scholar
• El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol. Res.37(Suppl. 2), S88–S94 (2007).
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology132(7), 2557–2576 (2007).
   PubMed Web of Science ®Google Scholar
• Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J. Hepatol.37(6), 806–813 (2002).
   PubMed Web of Science ®Google Scholar
• Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. J. Clin. Gastroenterol.38(10 Suppl. 3), S158–S168 (2004).
   PubMed Web of Science ®Google Scholar
• Chang MH, Chen CJ, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan childhood hepatoma study group. N. Engl. J. Med.336(26), 1855–1859 (1997).
   PubMed Web of Science ®Google Scholar
• Ladep NG, Taylor-Robinson SD. Management of liver disease in Nigeria. Clin. Med.7(5), 439–441 (2007).
   PubMed Web of Science ®Google Scholar
• Onyekwere CA, Anomneze EE, Wali SS. Prevalence of serological markers of chronic hepatitis B virus infection in diabetics in the Lagos University Teaching Hospital, Lagos. Niger. Postgrad. Med. J.9(3), 129–133 (2002).
   PubMedGoogle Scholar
• Groopman JD, Scholl P, Wang JS. Epidemiology of human aflatoxin exposures and their relationship to liver cancer. Prog. Clin. Biol. Res.395, 211–222 (1996).
   PubMedGoogle Scholar
• Ikai I, Itai Y, Okita K et al. Report of the 15th follow-up survey of primary liver cancer. Hepatol. Res.28(1), 21–29 (2004).
   PubMed Web of Science ®Google Scholar
• Wilson JF. Liver cancer on the rise. Ann. Intern. Med.142(12 Pt 1), 1029–1032 (2005).
   PubMed Web of Science ®Google Scholar
• Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979–1994. Lancet350(9085), 1142–1143 (1997).
   PubMed Web of Science ®Google Scholar
• Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La VC. Trends in mortality from hepatocellular carcinoma in Europe, 1980–2004. Hepatology48(1), 137–145 (2008).
   PubMed Web of Science ®Google Scholar
• Yu MW, Chen CJ. Elevated serum testosterone levels and risk of hepatocellular carcinoma. Cancer Res.53(4), 790–794 (1993).
   PubMed Web of Science ®Google Scholar
• Naugler WE, Sakurai T, Kim S et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science317(5834), 121–124 (2007).
   PubMed Web of Science ®Google Scholar
• Liu WH, Yeh SH, Lu CC et al. MicroRNA-18a prevents estrogen receptor-α expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology136(2), 683–693 (2009).
   PubMed Web of Science ®Google Scholar
• Yang WJ, Chang CJ, Yeh SH et al. Hepatitis B virus X protein enhances the transcriptional activity of the androgen receptor through c-Src and glycogen synthase kinase-3β kinase pathways. Hepatology49(5), 1515–1524 (2009).
   PubMed Web of Science ®Google Scholar
• Chiu CM, Yeh SH, Chen PJ et al. Hepatitis B virus X protein enhances androgen receptor-responsive gene expression depending on androgen level. Proc. Natl Acad. Sci. USA104(8), 2571–2578 (2007).
   PubMed Web of Science ®Google Scholar
• Simonetti RG, Camma C, Fiorello F, Politi F, D’Amico G, Pagliaro L. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig. Dis. Sci.36(7), 962–972 (1991).
   PubMed Web of Science ®Google Scholar
• Tiribelli C, Melato M, Croce LS, Giarelli L, Okuda K, Ohnishi K. Prevalence of hepatocellular carcinoma and relation to cirrhosis: comparison of two different cities of the world – Trieste, Italy, and Chiba, Japan. Hepatology10(6), 998–1002 (1989).
   PubMed Web of Science ®Google Scholar
• Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology127(5 Suppl. 1), S35–S50 (2004).
   PubMed Web of Science ®Google Scholar
• Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut53(5), 744–749 (2004).
   PubMed Web of Science ®Google Scholar
• Bolondi L, Sofia S, Siringo S et al. Surveillance program of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut48(2), 251–259 (2001).
   PubMed Web of Science ®Google Scholar
• Tsai JF, Jeng JE, Ho MS et al. Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. Br. J. Cancer76(7), 968–974 (1997).
   PubMed Web of Science ®Google Scholar
• Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet2(8256), 1129–1133 (1981).
   PubMed Web of Science ®Google Scholar
• Realdi G, Fattovich G, Hadziyannis S et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J. Hepatol.21(4), 656–666 (1994).
   PubMed Web of Science ®Google Scholar
• Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am. J. Gastroenterol.97(11), 2886–2895 (2002).
   PubMed Web of Science ®Google Scholar
• Kao JH, Chen DS. Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. Liver Int.25(4), 696–703 (2005).
   PubMed Web of Science ®Google Scholar
• Liu CJ, Kao JH. Hepatitis B virus-related hepatocellular carcinoma: epidemiology and pathogenic role of viral factors. J. Chin Med. Assoc.70(4), 141–145 (2007).
   PubMedGoogle Scholar
• Wu BK, Li CC, Chen HJ et al. Blocking of G1/S transition and cell death in the regenerating liver of hepatitis B virus X protein transgenic mice. Biochem. Biophys. Res. Commun.340(3), 916–928 (2006).
   PubMed Web of Science ®Google Scholar
• McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology49(5 Suppl.), S45–S55 (2009).
   PubMed Web of Science ®Google Scholar
• Shinkai N, Tanaka Y, Ito K et al. Influence of hepatitis B virus X and core promoter mutations on hepatocellular carcinoma among patients infected with subgenotype C2. J. Clin. Microbiol.45(10), 3191–3197 (2007).
   PubMed Web of Science ®Google Scholar
• Yang HI, Lu SN, Liaw YF et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N. Engl. J. Med.347(3), 168–174 (2002).
   PubMed Web of Science ®Google Scholar
• Yuen MF, Tanaka Y, Fong DY et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J. Hepatol.50(1), 80–88 (2009).
   PubMed Web of Science ®Google Scholar
• Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA295(1), 65–73 (2006).
   PubMed Web of Science ®Google Scholar
• Yu MW, Yeh SH, Chen PJ et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J. Natl Cancer Inst.97(4), 265–272 (2005).
   PubMed Web of Science ®Google Scholar
• Yang HI, Yeh SH, Chen PJ et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J. Natl Cancer Inst.100(16), 1134–1143 (2008).
   PubMed Web of Science ®Google Scholar
• Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology118(3), 554–559 (2000).
   PubMed Web of Science ®Google Scholar
• Liu CJ, Chen BF, Chen PJ et al. Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case–control study. J. Infect. Dis.194(5), 594–599 (2006).
   PubMed Web of Science ®Google Scholar
• Chen BF, Liu CJ, Jow GM, Chen PJ, Kao JH, Chen DS. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology130(4), 1153–1168 (2006).
   PubMed Web of Science ®Google Scholar
• Chen CH, Hung CH, Lee CM et al. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology133(5), 1466–1474 (2007).
   PubMed Web of Science ®Google Scholar
• Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology124(2), 327–334 (2003).
   PubMed Web of Science ®Google Scholar
• Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med.351(15), 1521–1531 (2004).
   PubMed Web of Science ®Google Scholar
• Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis.5(9), 558–567 (2005).
   PubMed Web of Science ®Google Scholar
• Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology21(3), 650–655 (1995).
   PubMed Web of Science ®Google Scholar
• Tradati F, Colombo M, Mannucci PM et al. A prospective multicenter study of hepatocellular carcinoma in italian hemophiliacs with chronic hepatitis C. The study group of the association of Italian hemophilia centers. Blood91(4), 1173–1177 (1998).
   PubMed Web of Science ®Google Scholar
• Tsukuma H, Hiyama T, Tanaka S et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N. Engl. J. Med.328(25), 1797–1801 (1993).
   PubMed Web of Science ®Google Scholar
• Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LA. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann. NY Acad. Sci.963, 13–20 (2002).
   PubMed Web of Science ®Google Scholar
• Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N. Engl. J. Med.332(22), 1463–1466 (1995).
   PubMed Web of Science ®Google Scholar
• De Mitri MS, Poussin K, Baccarini P et al. HCV-associated liver cancer without cirrhosis. Lancet345(8947), 413–415 (1995).
   PubMed Web of Science ®Google Scholar
• Lemon SM, Lerat H, Weinman SA, Honda M. A transgenic mouse model of steatosis and hepatocellular carcinoma associated with chronic hepatitis C virus infection in humans. Trans. Am. Clin. Climatol. Assoc.111, 146–156 (2000).
   PubMedGoogle Scholar
• Benvegnu L, Pontisso P, Cavalletto D, Noventa F, Chemello L, Alberti A. Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology25(1), 211–215 (1997).
   PubMed Web of Science ®Google Scholar
• Tanaka K, Ikematsu H, Hirohata T, Kashiwagi S. Hepatitis C virus infection and risk of hepatocellular carcinoma among Japanese: possible role of type 1b (II) infection. J. Natl Cancer Inst.88(11), 742–746 (1996).
   PubMedGoogle Scholar
• Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int. J. Cancer75(3), 347–354 (1998).
   PubMed Web of Science ®Google Scholar
• MacDonald DC, Nelson M, Bower M, Powles T. Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era. World J. Gastroenterol.14(11), 1657–1663 (2008).
   PubMed Web of Science ®Google Scholar
• Bugianesi E, Leone N, Vanni E et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology123(1), 134–140 (2002).
   PubMed Web of Science ®Google Scholar
• Hashimoto E, Yatsuji S, Tobari M et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J. Gastroenterol.44(Suppl. 19), 89–95 (2009).
   PubMed Web of Science ®Google Scholar
• Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med.348(17), 1625–1638 (2003).
   PubMed Web of Science ®Google Scholar
• Moller H, Mellemgaard A, Lindvig K, Olsen JH. Obesity and cancer risk: a Danish record-linkage study. Eur. J. Cancer30A(3), 344–350 (1994).
   PubMed Web of Science ®Google Scholar
• Wolk A, Gridley G, Svensson M et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control12(1), 13–21 (2001).
   PubMed Web of Science ®Google Scholar
• El Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology126(2), 460–468 (2004).
   PubMed Web of Science ®Google Scholar
• Malik SM, Gupte PA, de Vera ME, Ahmad J. Outcomes following liver transplantation in patients with non-alcoholic steatohepatitis-related hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. DOI:10.1016/j.cgh.2009.02.025 (2009) (Epub ahead of print).
   Google Scholar
• Qian GS, Ross RK, Yu MC et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People’s Republic of China. Cancer Epidemiol. Biomarkers Prev.3(1), 3–10 (1994).
   PubMed Web of Science ®Google Scholar
• Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature350(6317), 429–431 (1991).
   PubMed Web of Science ®Google Scholar
• Wild CP, Turner PC. The toxicology of aflatoxins as a basis for public health decisions. Mutagenesis17(6), 471–481 (2002).
   PubMed Web of Science ®Google Scholar
• Donato F, Tagger A, Gelatti U et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am. J. Epidemiol.155(4), 323–331 (2002).
   PubMed Web of Science ®Google Scholar
• Cauza E, Peck-Radosavljevic M, Ulrich-Pur H et al. Mutations of the HFE gene in patients with hepatocellular carcinoma. Am. J. Gastroenterol.98(2), 442–447 (2003).
   PubMed Web of Science ®Google Scholar
• Willis G, Bardsley V, Fellows IW, Lonsdale R, Wimperis JZ, Jennings BA. Hepatocellular carcinoma and the penetrance of HFE C282Y mutations: a cross sectional study. BMC Gastroenterol.5, 17 (2005).
   PubMed Web of Science ®Google Scholar
• Gomaa AI, Khan SA, Leen EL, Waked I, Taylor-Robinson SD. Diagnosis of hepatocellular carcinoma. World J. Gastroenterol.15(11), 1301–1314 (2009).
   PubMed Web of Science ®Google Scholar
• Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology31(2), 330–335 (2000).
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol.35(3), 421–430 (2001).
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology42(5), 1208–1236 (2005).
   PubMed Web of Science ®Google Scholar
• Horigome H, Nomura T, Saso K, Itoh M, Joh T, Ohara H. Limitations of imaging diagnosis for small hepatocellular carcinoma: comparison with histological findings. J. Gastroenterol. Hepatol.14(6), 559–565 (1999).
   PubMed Web of Science ®Google Scholar
• Daniele B, Bencivenga A, Megna AS, Tinessa V. α-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology127(5 Suppl. 1), S108–S112 (2004).
   PubMed Web of Science ®Google Scholar
• Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology22(2), 432–438 (1995).
   PubMed Web of Science ®Google Scholar
• Trevisani F, D’Intino PE, Morselli-Labate AM et al. Serum α-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J. Hepatol.34(4), 570–575 (2001).
   PubMed Web of Science ®Google Scholar
• Lok AS, Lai CL. α-fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology9(1), 110–115 (1989).
   PubMed Web of Science ®Google Scholar
• Farinati F, Marino D, De GM et al. Diagnostic and prognostic role of α-fetoprotein in hepatocellular carcinoma: both or neither? Am. J. Gastroenterol.101(3), 524–532 (2006).
   PubMed Web of Science ®Google Scholar
• Grizzi F, Franceschini B, Hamrick C, Frezza EE, Cobos E, Chiriva-Internati M. Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma. J. Transl. Med.5, 3 (2007).
   PubMed Web of Science ®Google Scholar
• Marrero JA, Su GL, Wei W et al. Des-γ carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology37(5), 1114–1121 (2003).
   PubMed Web of Science ®Google Scholar
• Volk ML, Hernandez JC, Su GL, Lok AS, Marrero JA. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark.3(2), 79–87 (2007).
   PubMedGoogle Scholar
• Nakamura S, Nouso K, Sakaguchi K et al. Sensitivity and specificity of des-γ-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am. J. Gastroenterol.101(9), 2038–2043 (2006).
   PubMed Web of Science ®Google Scholar
• Hagiwara S, Kudo M, Kawasaki T et al. Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma. J. Gastroenterol.41(12), 1214–1219 (2006).
   PubMed Web of Science ®Google Scholar
• Kim dY, Paik YH, Ahn SH et al. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection. Oncology72(Suppl. 1), 52–57 (2007).
   PubMed Web of Science ®Google Scholar
• Miyaaki H, Nakashima O, Kurogi M, Eguchi K, Kojiro M. Lens culinaris agglutinin-reactive α-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma. J. Gastroenterol.42(12), 962–968 (2007).
   PubMed Web of Science ®Google Scholar
• Shirabe K, Itoh S, Yoshizumi T et al. The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-γ-carboxy prothrombin. J. Surg. Oncol.95(3), 235–240 (2007).
   PubMed Web of Science ®Google Scholar
• Harino Y, Fujii M, Imura S et al. The role of des-γ-carboxyprothrombin expression in hepatocellular carcinoma. Hepatogastroenterology55(85), 1385–1389 (2008).
   PubMedGoogle Scholar
• Khien VV, Mao HV, Chinh TT et al. Clinical evaluation of lentil lectin-reactive α-fetoprotein-L3 in histology-proven hepatocellular carcinoma. Int. J. Biol. Markers16(2), 105–111 (2001).
   PubMed Web of Science ®Google Scholar
• Kumada T, Nakano S, Takeda I et al. Clinical utility of Lens culinaris agglutinin-reactive α-fetoprotein in small hepatocellular carcinoma: special reference to imaging diagnosis. J. Hepatol.30(1), 125–130 (1999).
   PubMed Web of Science ®Google Scholar
• Sterling RK, Jeffers L, Gordon F et al. Utility of Lens culinaris agglutinin-reactive fraction of α-fetoprotein and des-γ-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin. Gastroenterol. Hepatol.7(1), 104–113 (2009).
   PubMed Web of Science ®Google Scholar
• Ishizuka H, Nakayama T, Matsuoka S et al. Prediction of the development of hepato-cellular-carcinoma in patients with liver cirrhosis by the serial determinations of serum α-L-fucosidase activity. Intern. Med.38(12), 927–931 (1999).
   PubMed Web of Science ®Google Scholar
• Tangkijvanich P, Tosukhowong P, Bunyongyod P et al. α-L-fucosidase as a serum marker of hepatocellular carcinoma in Thailand. Southeast Asian J. Trop. Med. Public Health30(1), 110–114 (1999).
   PubMedGoogle Scholar
• Wang JJ, Cao EH. Rapid kinetic rate assay of the serum α-L-fucosidase in patients with hepatocellular carcinoma by using a novel substrate. Clin. Chim. Acta.347(1–2), 103–109 (2004).
   PubMed Web of Science ®Google Scholar
• el-Houseini ME, Mohammed MS, Elshemey WM, Hussein TD, Desouky OS, Elsayed AA. Enhanced detection of hepatocellular carcinoma. Cancer Control12(4), 248–253 (2005).
   PubMedGoogle Scholar
• Bukofzer S, Stass PM, Kew MC, de BM, Groeneveld HT. α-L-fucosidase as a serum marker of hepatocellular carcinoma in southern African blacks. Br. J. Cancer59(3), 417–420 (1989).
   PubMed Web of Science ®Google Scholar
• Chignard N, Beretta L. Proteomics for hepatocellular carcinoma marker discovery. Gastroenterology127(5 Suppl. 1), S120–S125 (2004).
   PubMed Web of Science ®Google Scholar
• Zinkin NT, Grall F, Bhaskar K et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin. Cancer Res.14(2), 470–477 (2008).
   PubMed Web of Science ®Google Scholar
• Geng X, Wang F, Li YG, Zhu GP, Zhang WM. SELDI-TOF MS proteinchip technology for screening of serum markers of HBV-induced hepatocellular carcinoma. J. Exp. Clin. Cancer Res.26(4), 505–508 (2007).
   PubMed Web of Science ®Google Scholar
• Chaerkady R, Harsha HC, Nalli A et al. A quantitative proteomic approach for identification of potential biomarkers in hepatocellular carcinoma. J. Proteome Res.7(10), 4289–4298 (2008).
   PubMed Web of Science ®Google Scholar
• Yang Y, Li C, Nie X et al. Metabonomic studies of human hepatocellular carcinoma using high-resolution magic-angle spinning 1H NMR spectroscopy in conjunction with multivariate data analysis. J. Proteome Res.6(7), 2605–2614 (2007).
   PubMed Web of Science ®Google Scholar
• Soper R, Himmelreich U, Painter D et al. Pathology of hepatocellular carcinoma and its precursors using proton magnetic resonance spectroscopy and a statistical classification strategy. Pathology34(5), 417–422 (2002).
   PubMed Web of Science ®Google Scholar
• Ariff B, Lloyd CR, Khan S et al. Imaging of liver cancer. World J. Gastroenterol.15(11), 1289–1300 (2009).
   PubMed Web of Science ®Google Scholar
• Colombo M, de FR, Del NE et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N. Engl. J. Med.325(10), 675–680 (1991).
   PubMed Web of Science ®Google Scholar
• Bennett GL, Krinsky GA, Abitbol RJ, Kim SY, Theise ND, Teperman LW. Sonographic detection of hepatocellular carcinoma and dysplastic nodules in cirrhosis: correlation of pretransplantation sonography and liver explant pathology in 200 patients. AJR Am. J. Roentgenol.179(1), 75–80 (2002).
   PubMed Web of Science ®Google Scholar
• Claudon M, Cosgrove D, Albrecht T et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) – update 2008. Ultraschall Med.29(1), 28–44 (2008).
   PubMed Web of Science ®Google Scholar
• Fan ZH, Chen MH, Dai Y et al. Evaluation of primary malignancies of the liver using contrast-enhanced sonography: correlation with pathology. AJR Am. J. Roentgenol.186(6), 1512–1519 (2006).
   PubMed Web of Science ®Google Scholar
• Morin SH, Lim AK, Cobbold JF, Taylor-Robinson SD. Use of second generation contrast-enhanced ultrasound in the assessment of focal liver lesions. World J. Gastroenterol.13(45), 5963–5970 (2007).
   PubMed Web of Science ®Google Scholar
• Pompili M, Riccardi L, Semeraro S et al. Contrast-enhanced ultrasound assessment of arterial vascularization of small nodules arising in the cirrhotic liver. Dig. Liver Dis.40(3), 206–215 (2008).
   PubMedGoogle Scholar
• Lopez HE, Vogl TJ, Bechstein WO et al. Biphasic spiral computed tomography for detection of hepatocellular carcinoma before resection or orthotopic liver transplantation. Invest. Radiol.33(4), 216–221 (1998).
   PubMed Web of Science ®Google Scholar
• Shapiro RS, Katz R, Mendelson DS, Halton KP, Schwartz ME, Miller CM. Detection of hepatocellular carcinoma in cirrhotic patients: sensitivity of CT and ultrasonography. J. Ultrasound Med.15(7), 497–502 (1996).
   PubMed Web of Science ®Google Scholar
• Lim JH, Kim CK, Lee WJ et al. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic livers: accuracy of helical CT in transplant patients. AJR Am. J. Roentgenol.175(3), 693–698 (2000).
   PubMed Web of Science ®Google Scholar
• Dai Y, Chen MH, Fan ZH, Yan K, Yin SS, Zhang XP. Diagnosis of small hepatic nodules detected by surveillance ultrasound in patients with cirrhosis: comparison between contrast-enhanced ultrasound and contrast-enhanced helical computed tomography. Hepatol. Res.38(3), 281–290 (2008).
   PubMed Web of Science ®Google Scholar
• Zhao H, Yao JL, Wang Y, Zhou KR. Detection of small hepatocellular carcinoma: comparison of dynamic enhancement magnetic resonance imaging and multiphase multirow-detector helical CT scanning. World J. Gastroenterol.13(8), 1252–1256 (2007).
   PubMed Web of Science ®Google Scholar
• Snowberger N, Chinnakotla S, Lepe RM et al. a fetoprotein, ultrasound, computerized tomography and magnetic resonance imaging for detection of hepatocellular carcinoma in patients with advanced cirrhosis. Aliment Pharmacol. Ther.26(9), 1187–1194 (2007).
   PubMed Web of Science ®Google Scholar
• Teefey SA, Hildeboldt CC, Dehdashti F et al. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology226(2), 533–542 (2003).
   PubMed Web of Science ®Google Scholar
• Ho CL, Chen S, Yeung DW, Cheng TK. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J. Nucl. Med.48(6), 902–909 (2007).
   PubMed Web of Science ®Google Scholar
• Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology49(2), 453–459 (2009).
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology134(6), 1752–1763 (2008).
   PubMed Web of Science ®Google Scholar
• Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat. Dis. Int.7(3), 237–257 (2008).
   PubMed Web of Science ®Google Scholar
• Bruix J, Castells A, Bosch J et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology111(4), 1018–1022 (1996).
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med.334(11), 693–699 (1996).
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Llovet JM, Miceli R et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol.10(1), 35–43 (2009).
   PubMed Web of Science ®Google Scholar
• Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology127(5 Suppl. 1), S179–S188 (2004).
   PubMed Web of Science ®Google Scholar
• Li YY, Sha WH, Zhou YJ, Nie YQ. Short and long term efficacy of high intensity focused ultrasound therapy for advanced hepatocellular carcinoma. J. Gastroenterol. Hepatol.22(12), 2148–2154 (2007).
   PubMed Web of Science ®Google Scholar
• Yao CL, Trinh T, Wong GT, Irwin MG. Anaesthesia for high intensity focused ultrasound (HIFU) therapy. Anaesthesia63(8), 865–872 (2008).
   PubMed Web of Science ®Google Scholar
• Zhu H, Zhou K, Zhang L et al. High intensity focused ultrasound (HIFU) therapy for local treatment of hepatocellular carcinoma: Role of partial rib resection. Eur. J. Radiol. DOI: 10.1016/j.ejrad.2008.07.003 (2008) (Epub ahead of print).
   Google Scholar
• Dick EA, Joarder R, de JM et al. MR-guided laser thermal ablation of primary and secondary liver tumours. Clin. Radiol.58(2), 112–120 (2003).
   PubMed Web of Science ®Google Scholar
• Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials. Aliment Pharmacol. Ther.23(11), 1535–1547 (2006).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med.359(4), 378–390 (2008).
   PubMed Web of Science ®Google Scholar
• Thomas MB, Chadha R, Glover K et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer110(5), 1059–1067 (2007).
   PubMed Web of Science ®Google Scholar